查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1820491

全球老年黄斑部病变 (AMD) 治疗市场研究报告 - 产业分析、规模、份额、成长、趋势及预测（2025 年至 2033 年）

Global Age Related Macular Degeneration (AMD) Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 155 Pages | 商品交期: 最快1-2个工作天内

价格

全球老年黄斑部病变 (AMD) 治疗市场预计将大幅成长，到 2033 年将达到 277.2 亿美元，高于 2024 年的 144.9 亿美元。预计该市场在 2025 年至 2033 年期间的年复合成长率(CAGR) 为 7.48%。

老年黄斑部病变 (AMD) 治疗市场正在快速发展，这得益于人口老化导致的 AMD 盛行率不断上升，以及人们对视力和生活品质的日益重视。治疗创新包括抗 VEGF 药物、基因疗法以及针对干性和湿性 AMD 潜在病理生理机制的新型药物传递系统。分子生物学和生物标记识别的进步使得个人化治疗方法和早期介入成为可能。缓释植入物和微创给药技术正在提高患者的依从性和治疗效果。

光学相干断层扫描 (OCT) 等诊断影像技术与治疗监测的结合，正在提高疾病管理的精确度。再生医学和干细胞疗法的研究有望为视网膜功能恢復带来希望。监管审批和报销政策正在促进市场准入和应用。此外，认知度的提高和筛检计画的发展，正在推动早期诊断和治疗的发展。

製药公司、研究机构和医疗保健提供者之间的合作正在加速临床试验和产品开发。由于AMD仍然是全球视力丧失的主要原因，治疗市场有望实现显着成长，提供创新解决方案，满足尚未满足的医疗需求并改善患者的生活品质。

我们的报告经过精心设计，旨在为客户提供关于各个行业和市场的全面且切实可行的洞察。每份报告都包含几个关键部分，以确保客户全面了解市场格局：

市场概况：对市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本部分探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准，将市场细分为不同的细分市场。此分析重点在于突出每个细分市场的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本部分深入分析了领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，对特定时期的市场规模和成长趋势进行预测。这包括定量分析和图形表示，以说明未来的市场发展轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前及新兴市场趋势、技术创新和潜在投资领域。本部分提供对未来市场发展和成长前景的洞察。

涵盖的细分市场列表

年龄相关性黄斑部病变 (AMD) 治疗市场报告的此部分提供了国家和地区层面的细分详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按产品

  • 艾莉亚
  • 乐康
  • 贝奥武
  • 瓦比斯莫
  • 西弗雷
  • 阿瓦斯汀
  • 其他产品

依疾病类型

  • 湿性AMD
  • 干性 AMD

按年龄组

  • 50-64岁
  • 65-74岁
  • 75岁以上

按配销通路

  • 医院药房
  • 专业药局和零售药局
  • 电子商务
  • 报告中介绍的公司列表
  • Amgen Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biocon Biologics Ltd., Biogen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group, Novartis AG, Pfizer Inc。

如果您有任何客製化需求，请联络我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告描述
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究流程
    • 市场研究方法

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：年龄相关性黄斑部病变 (AMD) 治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按产品进行市场吸引力分析
    • 依疾病类型分析市场吸引力
    • 按年龄分析市场吸引力
    • 按配销通路分析市场吸引力
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料製造商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第五章：全球老年性黄斑部病变（AMD）治疗市场分析：依产品

  • 按产品概览
  • 按产品进行的历史和预测数据分析
  • 艾莉亚
  • 乐康
  • 贝奥武
  • 瓦比斯莫
  • 西弗雷
  • 阿瓦斯汀
  • 其他产品

第六章：全球老年性黄斑部病变（AMD）治疗市场分析：依疾病类型

  • 依疾病类型概述
  • 依疾病类型分析历史和预测数据
  • 湿性AMD
  • 干性 AMD

第七章：全球老年黄斑部病变（AMD）治疗市场分析：依年龄组

  • 按年龄组别概览
  • 按年龄组别进行的历史和预测资料分析
  • 50-64岁
  • 65-74岁
  • 75岁以上

第 8 章：全球老年性黄斑部病变 (AMD) 治疗市场分析：按分销管道

  • 按配销通路概览
  • 按配销通路进行历史和预测资料分析
  • 医院药房
  • 专业药局和零售药局
  • 电子商务

第九章：全球老年性黄斑部病变（AMD）治疗市场分析：按地区

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美各细分市场销售分析
    • 北美各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲各细分市场销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区分部销售分析
    • 亚太地区国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲分部销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东和非洲其他地区销售分析

第 10 章：老年性黄斑部病变 (AMD) 治疗公司的竞争格局

  • 老年黄斑部病变（AMD）治疗市场竞争
  • 伙伴关係/合作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Amgen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Apellis Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Biocon Biologics Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Biogen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Celltrion Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • F. Hoffmann-La Roche Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Formycon AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Regeneron Pharmaceuticals Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sandoz Group AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • STADA Arzneimittel AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Xbrane Biopharma AB
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，或者在私人公司的情况下可能不涵盖

Product Code: VMR112117402

Global Age Related Macular Degeneration (AMD) Therapeutics Market is poised to witness substantial growth, reaching a value of USD 27.72 Billion by the year 2033, up from USD 14.49 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 7.48% between 2025 and 2033.

The age-related macular degeneration (AMD) therapeutics market is advancing rapidly, driven by the increasing prevalence of AMD due to aging populations and the growing focus on preserving vision and quality of life. Therapeutic innovations encompass anti-VEGF agents, gene therapies, and novel drug delivery systems targeting the underlying pathophysiology of both dry and wet AMD forms. Advances in molecular biology and biomarker identification are enabling personalized treatment approaches and earlier intervention. Sustained-release implants and minimally invasive administration techniques are improving patient compliance and treatment outcomes.

The integration of diagnostic imaging technologies, such as optical coherence tomography (OCT), with therapeutic monitoring is enhancing disease management precision. Research into regenerative medicine and stem cell therapies holds promise for restoring retinal function. Regulatory approvals and reimbursement policies are facilitating market access and adoption. Additionally, increasing awareness and screening programs are driving early diagnosis and treatment initiation.

Collaborations among pharmaceutical companies, research institutions, and healthcare providers are accelerating clinical trials and product development. As AMD remains a leading cause of vision loss globally, the therapeutics market is poised for significant growth, delivering innovative solutions that address unmet medical needs and improve patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Age Related Macular Degeneration (AMD) Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Eylea
  • Lucentis
  • Beovu
  • Vabysmo
  • Syfovre
  • Avastin
  • Other Products

By Disease Type

  • Wet AMD
  • Dry AMD

By Age Group

  • 50-64 Years
  • 65-74 Years
  • 75 and Above

By Distribution Channel

  • Hospital Pharmacies
  • Specialty and Retail Pharmacies
  • E-Commerce
  • List of Companies Profiled in the report
  • Amgen Inc., Apellis Pharmaceuticals Inc., Bayer AG, Biocon Biologics Ltd., Biogen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd, Formycon AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz Group AG, STADA Arzneimittel AG, Xbrane Biopharma AB

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Disease Type
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel
    • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Eylea Historic and Forecast Sales By Regions
  • 5.4. Lucentis Historic and Forecast Sales By Regions
  • 5.5. Beovu Historic and Forecast Sales By Regions
  • 5.6. Vabysmo Historic and Forecast Sales By Regions
  • 5.7. Syfovre Historic and Forecast Sales By Regions
  • 5.8. Avastin Historic and Forecast Sales By Regions
  • 5.9. Other Products Historic and Forecast Sales By Regions

6. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

  • 6.1. Overview By Disease Type
  • 6.2. Historical and Forecast Data Analysis By Disease Type
  • 6.3. Wet AMD Historic and Forecast Sales By Regions
  • 6.4. Dry AMD Historic and Forecast Sales By Regions

7. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. 50-64 Years Historic and Forecast Sales By Regions
  • 7.4. 65-74 Years Historic and Forecast Sales By Regions
  • 7.5. 75 and Above Historic and Forecast Sales By Regions

8. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1. Overview By Distribution Channel
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel
  • 8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 8.4. Specialty and Retail Pharmacies Historic and Forecast Sales By Regions
  • 8.5. E-Commerce Historic and Forecast Sales By Regions

9. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS COMPANIES

  • 10.1. Age Related Macular Degeneration (AMD) Therapeutics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF AGE RELATED MACULAR DEGENERATION (AMD) THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Bayer AG
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Biocon Biologics Ltd.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Biogen Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Celltrion Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. F. Hoffmann-La Roche Ltd
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Formycon AG
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Novartis AG
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Pfizer Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Regeneron Pharmaceuticals Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Sandoz Group AG
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. STADA Arzneimittel AG
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. Xbrane Biopharma AB
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Product (USD MN)
  • Eylea Market Sales By Geography (USD MN)
  • Lucentis Market Sales By Geography (USD MN)
  • Beovu Market Sales By Geography (USD MN)
  • Vabysmo Market Sales By Geography (USD MN)
  • Syfovre Market Sales By Geography (USD MN)
  • Avastin Market Sales By Geography (USD MN)
  • Other Products Market Sales By Geography (USD MN)
  • Analysis By Disease Type (USD MN)
  • Wet AMD Market Sales By Geography (USD MN)
  • Dry AMD Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • 50-64 Years Market Sales By Geography (USD MN)
  • 65-74 Years Market Sales By Geography (USD MN)
  • 75 and Above Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Specialty and Retail Pharmacies Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Age Related Macular Degeneration (AMD) Therapeutics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Age Related Macular Degeneration (AMD) Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Age Related Macular Degeneration (AMD) Therapeutics Market Size, By Regions (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Regions
  • Value Chain Analysis
  • Global Market Analysis By Product (USD MN)
  • Eylea Market Sales By Geography (USD MN)
  • Lucentis Market Sales By Geography (USD MN)
  • Beovu Market Sales By Geography (USD MN)
  • Vabysmo Market Sales By Geography (USD MN)
  • Syfovre Market Sales By Geography (USD MN)
  • Avastin Market Sales By Geography (USD MN)
  • Other Products Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Type (USD MN)
  • Wet AMD Market Sales By Geography (USD MN)
  • Dry AMD Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • 50-64 Years Market Sales By Geography (USD MN)
  • 65-74 Years Market Sales By Geography (USD MN)
  • 75 and Above Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Specialty and Retail Pharmacies Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.